The estimated Net Worth of Oliver Fetzer is at least $871 Mille dollars as of 13 June 2019. Oliver Fetzer owns over 1,525 units of Arena Pharmaceuticals Inc stock worth over $417,858 and over the last 8 years he sold ARNA stock worth over $85,232. In addition, he makes $367,633 as Independent Director at Arena Pharmaceuticals Inc.
Oliver has made over 1 trades of the Arena Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,525 units of ARNA stock worth $85,232 on 13 June 2019.
The largest trade he's ever made was selling 1,525 units of Arena Pharmaceuticals Inc stock on 13 June 2019 worth over $85,232. On average, Oliver trades about 218 units every 0 days since 2017. As of 13 June 2019 he still owns at least 4,179 units of Arena Pharmaceuticals Inc stock.
You can see the complete history of Oliver Fetzer stock trades at the bottom of the page.
Dr. Oliver S. Fetzer Ph.D. serves as Independent Director of the Company. Dr. Fetzer has served on our Board of Directors since February 2017. He has served as the Chief Executive Officer of Synthetic Genomics, Inc., a private synthetic biology company commercializing genomic technologies, since November 2014. Prior to Synthetic Genomics, Dr. Fetzer was President and Chief Executive Officer of Cerulean Pharma Inc., a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics, from April 2009 to October 2014. Prior to Cerulean Pharma, Dr. Fetzer served in a variety of positions at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Research & Development, Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Business Development. Dr. Fetzer began his career in 1993 in various positions of increasing responsibility at the Boston Consulting Group (BCG), a global leading management consulting firm, including Consultant, Project Leader, Principal, Partner and Managing Director. Dr. Fetzer served on the boards of Auxilium Pharmaceuticals, Inc. from 2005 to 2015 and of Cerulean Pharma, Inc. from 2009 to 2014, and has served on the board of Tecan Group AG, a publicly traded provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics, since 2011. Dr. Fetzer received a B.S. in Biochemistry from the College of Charleston, a Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an M.B.A. from Carnegie Mellon University.
As the Independent Director of Arena Pharmaceuticals Inc, the total compensation of Oliver Fetzer at Arena Pharmaceuticals Inc is $367,633. There are 14 executives at Arena Pharmaceuticals Inc getting paid more, with Amit Munshi having the highest compensation of $8,931,400.
Oliver Fetzer is 56, he's been the Independent Director of Arena Pharmaceuticals Inc since 2017. There are 4 older and 9 younger executives at Arena Pharmaceuticals Inc. The oldest executive at Arena Pharmaceuticals Inc is Garry Neil, 67, who is the Independent Director.
Oliver's mailing address filed with the SEC is C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO, CA, 92121.
Over the last 21 years, insiders at Arena Pharmaceuticals Inc have traded over $9,243,184 worth of Arena Pharmaceuticals Inc stock and bought 78,040 units worth $252,505 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Manmeet Singh Soni e Garry Arthur Neil. On average, Arena Pharmaceuticals Inc executives and independent directors trade stock every 39 days with the average trade being worth of $3,133,387. The most recent stock trade was executed by Amit Munshi on 16 August 2021, trading 1,000 units of ARNA stock currently worth $48,190.
Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas
Arena Pharmaceuticals Inc executives and other stock owners filed with the SEC include: